Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 947-950

  Sleijfer, S ^a   Willemse, P H B ^a   De Vries, E G E ^a   Van Der Graaf, W T A ^a   Schraffordt Koops, H ^a   Mulder, N H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Carboplatin; Cyclophosphamide; Seminoma; Vincristine

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; VINCRISTINE;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG EFFICACY; FOLLOW UP; GRANULOCYTOPENIA; HEART ARREST; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; OUTPATIENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SEMINOMA; THROMBOCYTOPENIA;

EID: 0029761999     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.462     Document Type: Article

References (24)

1. AMATO RJ, ELLERHORST J, BANKS M AND LOGOTHETIS CJ. (1995). Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Eur. J. Cancer, 31A, 2223-2228.
2. BIESMA B, WILLEMSE PHB, MULDER NH, SLEIJFER DTh, GIETEMA JA, MULL R, LIMBURG PC, BOUMA J, VELLENGA E AND DE VRIES EGE. (1992). Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood, 80, 1141-1148.
3. CALVERT AH, HARLAND SJ, NEWELL DR, SIDIK ZH AND HARRAP KR. (1985). Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer. Treat. Rev., 12, (suppl A), 51-57.
4. DE VRIES EGE, BIESMA B, WILLEMSE PHB, MULDER NH, STERN AC, AALDERS JG AND VELLENGA E. (1991). A double-blind placebo-controlled study with GM-CSF during chemotherapy for ovarian carcinoma. Cancer Res., 51, 116-122.
5. FOSSÅ SD, BORGE L, AASS N, JOHANNESSEN NB, STENWIG AE AND KAALHUS O. (1987). The treatment of advanced metastatic seminoma: experience in 55 cases. J. Clin. Oncol., 5, 1071-1077.
6. FOSSÅ SD, AASS N AND KAALHUS O. (1989). Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int. J. Radiat. Oncol. Biol. Phys., 16, 383-388.
7. FOSSÅ SD, DROZ JP, STOTER G, KAYE SB, VERMEYEEN K, SYLVESTER R AND THE MEMBERS OF THE EORTC GU GROUP (1995). Cisplatin, vincristine, ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. Br. J. Cancer, 71, 619-624.
8. GIETEMA JA, WIELEMSE PHB, MULDER NH, OLDHOFF J, DE VRIES EGE AND SLEIJFER DTH. (1991). Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma. Eur. J. Cancer, 27, 1376-1379.
9. HORWICH A, DEARNALEY DP, DUCHESNE GM, WILLIAMS M, BRADA M AND PECKHAM MJ. (1989). Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J. Clin. Oncol., 1, 1150-1156.
10. HORWICH A, DEARNALEY DP, A'HERN R, MASON M, THOMAS G, JAY G AND NICHOLLS J. (1992). The activity of single-agent carboplatin in advanced seminoma. Eur. J. Cancer, 28A, 1307-1310.
11. KAMEN BA, FRENKEL E AND COLVIN OM. (1995). Ifosfamide: should the honeymoon be over? J. Clin. Oncol., 13, 307-309.
12. LOEHRER PJ, BIRCH R, WILLIAMS SD, GRECO FA AND EINHORN LH. (1987). Chemotherapy of metastatic seminoma: The South-eastern Cancer Study Group experience. J. Clin. Oncol., 5, 1212-1220.
13. LOGOTHETIS CJ, SAMUELS ML, OGDEN SL, DEXEUS FH AND CHONG CDK. (1987). Cyclophosphamide and sequential cisplatin for advanced seminoma: long term follow up in 52 patients. J. Urol., 138, 789-794.
14. MENCEL PJ, MOTZER RJ, MAZUMDAR M, VLAMIS V, BAJORIN DF AND BOSL GJ. (1994). Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J. Clin. Oncol., 12, 120-126.
15. MOTZER R, BOSL G, HEELAN R, FAIR W, WHITMORE W, SOGANI P, HERR H AND MORSE M. (1987). Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J. Clin. Oncol., 5, 1064-1070.
16. PECKHAM MJ, MC ELWAIN TJ, BARRETT A AND HENDRY WF, (1979). Combined management of the malignant teratoma of the testis. Lancet, 2, 267-270.
17. SCHMOLL HJ, HARSTRICK A, BOKEMEYER C, DIECKMANN KP, CLEMM C, BERDEL WE, SOUCHON R, SCHÖBER C, WILKE H AND POLIWODA H. (1993). Single-agent carboplatinum for advanced seminoma. Cancer, 72, 237-243.
18. SCHNEIDER W, RODENSKY P AND LIEBERMAN B. (1964). Regression, relapse and regression of metastatic seminoma by cyclophosphamide (NSC-26271). Cancer Chemother. Rep., 41, 37-40.
19. SCHULTZ SM, EINHORN LH, CONCES DJ, WILLIAMS SD AND LOEHRER PJ. (1989). Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J. Clin. Oncol., 7, 1497-1503.
20. THOMAS GM, RIDER WD, DEMBO AJ, CUMMINGS BJ, I GOSPODAROWICZ M, HAWKINS NV, HERMAN JG AND KEEN CW. (1982). Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J. Radiat. Oncol. Biol. Phys., 8, 163-174.
21. VELDHUIS GJ, WILLEMSE PHB, VAN GAMEREN MM, AALDERS JG, MULDER NH, MULL B, BIESMA B AND DE VRIES EGE. (1995). Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. J. Clin. Oncol., 13, 733-740.
22. WETTLAUFER JN. (1984). The management of advanced seminoma. Semin. Urol., II, 257-263.
23. WORLD HEALTH ORGANIZATION. (1978). Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication 48. NijhofT: The Hague, The Netherlands.
24. WILLIAMS SD AND ROTH BJ. (1991). Chemotherapy of testis cancer: a review. Int. J. Radiat. Oncol. Biol. Phys., 22, 213-217.